Tadalafil

Product NDC
50436-0372
Requested package NDC
50436-0372-2
11-digit product format
504360372
Labeler code
50436
Product ID
50436-0372_4bfd6267-6bbb-4590-ac91-84a09e9413f1
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Tadalafil
Dosage form
TABLET, FILM COATED
Route
ORAL
Labeler
Unit Dose Services
Application
ANDA209167
Marketing category
ANDA
Marketing start
2019-03-27
Marketing end
0000-00-00
Substance
TADALAFIL
Active strength
20 mg/1
Pharmacologic classes
Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2023-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded packagepackage50436-037250436-0372-2IInactivated by FDA2026-07-31

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209167-001TADALAFILTADALAFIL2.5MGTABLET / ORALAB12019-03-26
A209167-002TADALAFILTADALAFIL5MGTABLET / ORALAB12019-03-26
A209167-003TADALAFILTADALAFIL10MGTABLET / ORALAB12019-10-23
A209167-004TADALAFILTADALAFIL20MGTABLET / ORALAB12019-03-26

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 4 matching rows.

Application-product, TE code table
Application-productTE code
A209167-001AB1
A209167-002AB1
A209167-003AB1
A209167-004AB1

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-08-01 22:54:322026-06A209167-001TADALAFIL2.5MGTABLET / ORALAB12019-03-26a50c72e98297…
2026-08-01 22:54:322026-06A209167-002TADALAFIL5MGTABLET / ORALAB12019-03-26a50c72e98297…
2026-08-01 22:54:322026-06A209167-003TADALAFIL10MGTABLET / ORALAB12019-10-23a50c72e98297…
2026-08-01 22:54:322026-06A209167-004TADALAFIL20MGTABLET / ORALAB12019-03-26a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-08-01 22:54:322026-06A209167-001AB11a50c72e98297…
2026-08-01 22:54:322026-06A209167-002AB11a50c72e98297…
2026-08-01 22:54:322026-06A209167-003AB11a50c72e98297…
2026-08-01 22:54:322026-06A209167-004AB11a50c72e98297…

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 15 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TadalafilTADALAFILBryant Ranch Prepack07567ae5-7345-4ab1-9b2c-c586c4da04272026-06-24Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILBryant Ranch Prepackaa8d165b-0c7d-497a-b56a-7c62ebc0a5d22026-05-13Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILBryant Ranch Prepackf8def23c-55ea-4796-9735-dbcb251048352026-05-13Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILAccord Healthcare Inc.eedf3ad9-7d40-496d-b1a9-6200010c18e12026-04-16Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILPreferred Pharmaceuticals Inc.affacb88-4af3-4ce9-961b-7fc37b169e9a2026-01-12Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILNorthwind Health Company, LLCf3092f5a-b976-91ab-e053-2995a90a9b502026-01-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILNorthwind Health Company, LLCf317fe1e-d7c4-fb8b-e053-2a95a90a54452026-01-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILNuCare Pharmaceuticals,Inc.cf35291b-b05b-1182-e053-2995a90a8dee2025-02-10Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILNuCare Pharmaceuticals,Inc.9f83ea2e-8ee8-ab6d-e053-2995a90a1e962024-06-20Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILNuCare Pharmaceuticals,Inc.a0acad71-8ae3-2827-e053-2995a90a20b32024-06-20Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILProficient Rx LP7a105ef9-7129-4ce1-bd8d-ae316bf348e22022-11-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILProficient Rx LPb539e862-d5d4-4989-a3dd-1eba66285d532022-05-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILProficient Rx LP31c05a53-7282-46d0-81bd-108defe6fb382022-04-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILProficient Rx LP6fa9d4fa-86c9-4791-b28b-78e8b9341cea2022-04-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167
TadalafilTADALAFILAsclemed USA, Inc.aba646fe-70c2-1abb-e053-2995a90aa16d2022-01-28Warnings, Adverse reactionsExact identifier
application applno (ANDA): 209167
application number: ANDA209167

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b90b74cb-f6c8-3798-d11c-73b8768b278aProduct name820250317
0fe0157c-95a7-4870-ae64-de9f3fa874aeProduct name120250227
20ae0006-d78c-4dba-9e3e-6ae424841903Product name120250127
b86a08b7-54cc-440b-ad4a-3e530ccd8324Product name620230421
7a02e74a-2844-42af-84a8-96bae57351cfProduct name120230313
928d249c-35c3-4d88-a9ef-cf2f2e31b96fProduct name120220706

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
50436-0372-12024-01-30C16284748780-11030e365-6b5e-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003
50436-0372-22024-01-30C16284748780-11030e365-6b5e-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003
50436-0372-32024-01-30C16284748780-11030e365-6b5e-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003
50436-0372-42024-01-30C16284748780-11030e365-6b5e-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003
50436-0372-52024-01-30C16284748780-11030e365-6b5e-111a-e063-dadaa90a10e2These highlights do not include all the information needed to use TADALAFIL TABLETS safely and effectively. See full prescribing information for TADALAFIL TABLETS. TADALAFIL tablets, for oral use Initial U.S. Approval: 2003

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50436-0372-1Tadalafil3 in 1 BOTTLETABLET, FILM COATED32
50436-0372-2Tadalafil6 in 1 BOTTLETABLET, FILM COATED62
50436-0372-3Tadalafil9 in 1 BOTTLETABLET, FILM COATED92
50436-0372-4Tadalafil18 in 1 BOTTLETABLET, FILM COATED182
50436-0372-5Tadalafil27 in 1 BOTTLETABLET, FILM COATED272

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50436-0372TADALAFIL TABLET, FILM COATED [UNIT DOSE SERVICES]2Legacy NDC, 5 package rows20220922_59bcf8b4-9829-4673-bd47-7dedb79a9548.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
402019tadalafil 20 MG Oral TabletPSN59bcf8b4-9829-4673-bd47-7dedb79a95482
402019tadalafil 20 MG Oral TabletSCD59bcf8b4-9829-4673-bd47-7dedb79a95482

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
50436-0372-2504360372026 TABLET, FILM COATED in 1 BOTTLE (50436-0372-2) 2022-09-210000-00-00NoNoCurrent